![Cencora Inc](/common/images/company/NY_COR.png)
UK MHRA marketing authorization follows recent European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) in the EU for the treatment of wet AMDInitial commercial launches of...
Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2024 on Wednesday, July 31, 2024, prior to the opening of trading on the New York...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.12 | 0.503416037397 | 222.48 | 226.95 | 221.52 | 1367138 | 223.81664432 | CS |
4 | -15.39 | -6.43959998326 | 238.99 | 241.2195 | 219.19 | 1409217 | 226.53364478 | CS |
12 | -16.4 | -6.83333333333 | 240 | 241.2195 | 214.7686 | 1541293 | 227.49038954 | CS |
26 | 5.32 | 2.43723657687 | 218.28 | 246.75 | 214.7686 | 1376064 | 231.21539137 | CS |
52 | 43.11 | 23.8849797773 | 180.49 | 246.75 | 171.65 | 1376269 | 215.16497595 | CS |
156 | 87.34 | 64.0980478497 | 136.26 | 246.75 | 134.05 | 1173004 | 203.98031426 | CS |
260 | 109.33 | 95.6769055745 | 114.27 | 246.75 | 90.07 | 682588 | 176.9027825 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.